Melasma
☆ 2022. gada Stiftung Warentest rezultātos no Vācijas patērētāju apmierinātība ar ModelDerm bija tikai nedaudz zemāka nekā ar maksas telemedicīnas konsultācijām.
Tā ir izplatīta slimība, ko novēro Āzijas sievietēm 40 gadu vecumā. Aplī esošais bojājums fotoattēlā ir tuvāk lentigo, nevis melasmai.
References
Tranexamic acid is a novel treatment option for melasma; however, there is no consensus on its use. This systematic review searched major databases for relevant publications to March 2016. Eleven studies with 667 participants were included. Pooled data from tranexamic acid-only observational studies with pre- and post-treatment Melasma Area and Severity Index (MASI) showed a decrease of 1.60 in MASI after treat?ment with tranexamic acid. The addition of tranexamic acid to routine treatment modalities resulted in a further decrease in MASI of 0.94. These results support the efficacy and safety of tranexamic acid, either alone or as an adjuvant to routine treatment modalities for melasma.
Pēdējā laikā low-fluence Q-switched Nd:YAG (LFQSNY) lāzers ir kļuvis populārs melasmas ārstēšanā, īpaši Āzijā. Daudzveidīgu pētījumu apkopošana bija sarežģīta, taču LFQSNY šķiet kopumā efektīva un droša melasmai salīdzinājumā ar tradicionālajām terapijām. Tomēr ir ziņots par dažiem plankumainas hipopigmentācijas gadījumiem kā LFQSNY blakusparādība, iespējams, augstas lāzera enerģijas dēļ. Agresīva LFQSNY lietošana var izraisīt arī hiperpigmentāciju no iekaisuma, īpaši tumšākos ādas toņos.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Pigmentācijas problēmas bieži tiek konstatētas primārajā aprūpē. Bieži sastopamie hiperpigmentācijas traucējumu veidi ir post-inflammatory hyperpigmentation, melasma, sunspots, freckles, and café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Melasmu nevar izārstēt ar lāzerterapiju noteiktu laiku, jo tā ir slimība, kurā nepārtraukti veidojas pigments. Tranksenēmskābe palīdz uzlabot pigmentācijas samazināšanos.
○ Ārstēšana
Dažās valstīs (piemēram, Japānā, Korejā) iekšķīgi lietojamā traneksāmskābe ir pieejama bez receptes un ir efektīva. Melasmas krēms ar traneksāmskābi un azelaīnskābi var būt daļēji noderīgs.
Hidrohinonu var lietot lokāli hiperpigmentācijas ārstēšanai, taču FDA apturēja ārpusbiržas produktus, kas satur hidrohinonu, no 2020. gada.
#Tranexamic acid [TRANSINO]
#Laser toning technique (low fluence QS1064 laser)
#Triluma